In 2017 Neuroplast completed its pre-clinical program for the indications Spinal Cord Injury and Amyotrophic Lateral Sclerosis. In these preclinical Proof-of-Concept studies, not any sign of toxicity and/or other safety issues could be found.
In 2017 no signs of toxicity or tumorgeneticy could be established in an extensive preclinical research protocol (CERB, France) with intrathecal applied Neuro-Cells.
Safety and efficacy of Neuro-Cells could be established in T-cell deficient rats with a balloon compressed induced SCI.
Safety and efficacy (superior to an intervention with riluzole) of Neuro-Cells could be established in the FUS-transgenic ALS-phenotype mice.